Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer, Neurology |
| Therapuetic Areas: | Neurology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 3/16/2019 |
| Start Date: | March 25, 2014 |
| End Date: | January 1, 2100 |
Exploratory Next Generation Sequencing to Identify Causative Variants for Taxane-Induced Peripheral Neuropathy From Breast Cancer Study E5103 Germline DNA Samples
This research trial studies whole exome sequencing in finding causative variants in germline
deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving
chemotherapy for breast cancer. Studying samples of germline DNA in the laboratory from
patients with peripheral neuropathy receiving paclitaxel for breast cancer may help doctors
learn more about changes that occur in DNA and identify biomarkers related to peripheral
neuropathy.
deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving
chemotherapy for breast cancer. Studying samples of germline DNA in the laboratory from
patients with peripheral neuropathy receiving paclitaxel for breast cancer may help doctors
learn more about changes that occur in DNA and identify biomarkers related to peripheral
neuropathy.
PRIMARY OBJECTIVES:
I. To identify, using next generation sequencing, rare variants of large effect size that
impact the risk of peripheral neuropathy in patients of African and European descent in the
clinical trial ECOG-5103 (E5103).
OUTLINE:
Previously collected germline DNA samples are analyzed via whole exome sequencing.
I. To identify, using next generation sequencing, rare variants of large effect size that
impact the risk of peripheral neuropathy in patients of African and European descent in the
clinical trial ECOG-5103 (E5103).
OUTLINE:
Previously collected germline DNA samples are analyzed via whole exome sequencing.
Inclusion Criteria:
- European American patients with DNA available and designated case or control
- African American patients with DNA available and designated case or control status
- Patients who developed grade 2-4 for African American (AA) and grade 3-4 for European
American (EA) peripheral neuropathy during their treatment with paclitaxel and who did
not develop peripheral neuropathy following a full course of treatment with paclitaxel
We found this trial at
1
site
Boston, Massachusetts 02215
Principal Investigator: Bryan P. Schneider
Phone: 317-274-6473
Click here to add this to my saved trials
